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Previewsshow that increased NADPH oxidase ac-
tivity, ROS intracellular concentration,
and NF-kB signaling in the APC-inacti-
vated intestinal cells are all dependent
on Rac1 expression. By modulating
intracellular ROS levels in vivo through
treatment with antioxidants and pro-
oxidants, they further demonstrate that
Rac1-driven ROS generation is essential
for the effect of APC loss on ISCs and pro-
genitors. In summary, through the elegant
use of various mutant mouse models, the
authors provide evidence that Rac1-
driven ROS production is required for
NF-kB activation and initiation of colon
tumorigenesis.
Although ROS involvement in tumori-
genesis has been known for decades,
ROSwere initially considered a byproduct
of cellular metabolism, contributing to tu-
mor initiation by inducing DNA damage,
e.g., as endogenous mutagenic agents.
More recently, ROS increase and DNA
damage accumulation have been shown
to be invariably associated with expres-
sion of activated oncogenes in normal
cells, a phenomenon that is perceived as
integral to tumor development. There is,
however, a second face to ROS, distinct
from that of damaging agents, which
sees them function as signaling mole-
cules in a variety of intracellular pathways636 Cell Stem Cell 12, June 6, 2013 ª2013 E(Giorgio et al., 2007). Accordingly,
increased ROSmight contribute to tumor-
igenesis by activating specific signaling
pathways, as Myant and colleagues
suggest here for NF-kB and colon
tumorigenesis.
The authors contribute to a further level
of understanding of ROS signaling, i.e. the
cellular context wherein ROS accumula-
tion becomes critical for transformation.
Fine mapping of the identity of tumori-
genic intestinal cells reveals that ROS
levels in the APC-deficient intestine were
particularly high at the crypt base, at cell
positions 1–3 (where Lgr5+ ISCs reside),
suggesting that deregulated ROS
signaling in the proliferating ISCs is critical
to colon tumorigenesis. However, it is also
clear that, under normal conditions,
context-dependent modifications of the
redox balance can influence critical SC
functions, including proliferation, differen-
tiation, and survival. SCs have smaller
mitochondrial DNA copy numbers and
higher expression levels of antioxidant
genes than their differentiated progeny,
which maintain intracellular ROS at low
levels. While this might result in an SC-
specific mechanism to preserve genome
and proteome integrity, it might also allow
tolerance to increased ROS levels, thus
providing SCs with the capacity to endurelsevier Inc.the hyperproliferative effect of ROS. Time
and technologies seem ripe to investigate
the biology of redox changes in SCs.REFERENCES
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Recently in Cell, Mitalipov and colleagues report an advance that has eluded scientists for over a decade—
the successful derivation of embryonic stem cell lines using somatic cell nuclear transfer, or SCNT (Tachibana
et al., 2013).After the isolation and propagation of hu-
man embryonic stem cells (ESCs) was
first reported in 1998, many stem cell
and reproductive biologists set their
sights on being the first to isolate ESCsfrom SCNT-generated (or ‘‘cloned’’) hu-
man embryos. SCNT is a technique where
the nucleus of a somatic cell is inserted
into a recipient oocyte. Then cleavage of
the oocyte containing the donor nucleuscan be induced to initiate embryogenesis,
which is supported by reprogramming
factors in the oocyte. At the time, SCNT
was the only potential source of pluripo-
tent cells genetically matched to an
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Previewsindividual for histocompatible cell trans-
plants. Thus generating SCNT-ESCs
became something of a holy grail, and
the public was keenly interested. Now,
14 years later, Mitalipov and colleagues
report that they have been able to effi-
ciently derive ESC lines from human em-
bryos generated by SCNT (Tachibana
et al., 2013).
Tachibana et al. (2013) report produc-
tion of human SCNT-ESCs with remark-
able efficiency. They produced a total of
six SCNT-ESC lines, starting with a total
of 28 oocytes derived from three egg
donors. Fetal dermal fibroblasts or
cultured skin fibroblasts were used as
the nuclear donor cells. They attributed
their success to overcoming challenges
that they believed had thwarted previous
attempts—namely the oocytes’ prema-
ture exit from meiosis and suboptimal
oocyte activation procedures. It is impor-
tant to note that this group is made up of
some of the most experienced nuclear
transfer scientists in the world who have
been responsible for many of the major
advances in primate reproductive cell
biology over the last two decades,
including the production of SCNT-ESCs
in the monkey (Byrne et al., 2007).
Mitalipov and colleagues spent con-
siderable effort optimizing their protocol,
usingmonkey oocytes in many of their ex-
periments to minimize their use of human
oocytes. One step they cite as especially
critical to their success was to more ef-
fectively activate oocytes by electrical
stimulation. Another barrier to success
they cite is the oocytes’ premature exit
from meiosis upon enucleation. They
report that treating the oocytes with
caffeine, a protein phosphatase inhibitor,
prevented premature exit from meiosis.
Another optimization step they reported
is the use of 10 nM Trichostatin A (TSA),
an inhibitor of histone deacetylase, to
enhance embryogenesis, as they had pre-
viously used in SCNT with monkey oo-
cytes. They also observed that performing
SCNTwith oocytes that might normally be
discarded was effective in their hands.
Specifically, 12 hours after activation of
oocytes with 6-methylaminopurine (6-
DMAP), one would expect two pronuclei
to form. However, the SCNT oocytes
that went on to formESC lineswith normal
chromosome numbers had zero, one, or
two pronuclei, or were already in cleav-
age. This suggests that the activation ofthe oocytes is not closely synchronized,
and that discarding oocytes with zero or
one pronuclei or cleaved cells could alter
the efficiency of SCNT. Overall, the study
reported a relatively small number of
SCNTs, which precludes any firm statisti-
cal conclusions; therefore, further studies
will be necessary to confirm the impor-
tance of factors identified for success. In
addition, concerns have been raised
about the duplication of figures in the
Tachibana paper that will require explana-
tion and independent genetic verification
of the results.
The cloning of an animal by transplan-
tation of differentiated nuclei into eggs
was pioneered by John Gurdon who
used it in amphibian cell reprogramming
(Gurdon, 1962). Then with the cloning of
‘‘Dolly the sheep’’ (Campbell et al., 1996)
came a veritable menagerie of cloned
mammals. SCNT-ESCs were isolated
and cultured from many of the cloned
species, including monkeys (Byrne et al.,
2007), suggesting it should be possible
to do the same for humans. In 2004, the
Korean veterinarian Woo-Suk Hwang
claimed to have isolated ESCs from
cloned human embryos. However, key
data were later found to be fabricated
and the papers were retracted. His group
did manage to produce one parthenoge-
netic ESC line from human blastocysts
as a result of activation of a recipient
oocyte rather than nuclear transfer (Kim
et al., 2007).
When Shinya Yamanaka reported the
reprogramming of human adult cells by
the introduction of only four transcription
factors (Takahashi et al., 2007), reprog-
ramming technology spectacularly leap-
frogged over SCNT. This development
lessened the urgency of establishing hu-
man SCNT-ESCs, and attention instead
became focused on improving factor-
mediated reprogramming technology
and evaluating the safety of induced
pluripotent cells (iPSCs) and their equiva-
lency to ESCs. In 2012, the Nobel Prize in
Physiology and Medicine was awarded to
Shinya Yamanaka and John Gurdon for
their achievements.
Nonetheless, a number of groups
made progress toward the goal of pro-
ducing SCNT-ESCs (reviewed by Gries-
hammer et al., 2011). Notably, despite
having relatively few oocytes available,
French et al. (2008) reported that 23%
of SCNTs they attempted resulted in hu-Cell Stem Ceman blastocyst stage embryos that had
the genomic contribution from the adult
cell donor. Noggle et al. (2011) observed
that enucleation of the oocyte prior to nu-
clear transfer resulted in embryos not
developing more than a few cleavage
divisions. If they left the oocyte nucleus
in place and transferred a somatic cell
nucleus, triploid blastocysts developed,
from which they derived triploid pluripo-
tent ESC lines. Although representing
a partial success in SCNT technology,
these triploid lines are not useful
therapeutically.
The current study signifies several
‘‘firsts.’’ It will now be possible to evaluate
how different reprogramming approaches
affect developmental capacity, genetic
stability, and graft survival by directly
comparing SCNT-ESCs and iPSCs
derived from the same donor. New re-
programming factors identified in oocytes
may be used to improve the efficiency and
speed of iPSC reprogramming. SCNT
may also provide a way of enabling cell
therapies for patients with mitochondrial
diseases because healthy mitochondria
will derive from the oocyte donor, which
isn’t the case for iPSC technology (see
Figure 1).
Perhaps most importantly, the study
supports the feasibility of using SCNT
for efficiently generating pluripotent cell
lines for cell replacement therapy. It is
also much more rapid than iPSC deriva-
tion, which could be crucial for patients
urgently needing autologous cell trans-
plants. The main constraint presently to
widespread application of SCNT is likely
to be the availability of mature, develop-
mentally competent human oocytes,
which will again raise commentary on
the financial and ethical issues of dona-
tion of human oocytes for research.
This is in large part due to the difficulty
in procuring sufficient numbers of mature
human oocytes to carry out what have
typically been low-efficiency experi-
ments. Recently, however, it was re-
ported that mouse ESCs and iPSCs
could produce viable oocytes and live,
healthy young (Hayashi et al., 2012). If
applied to human cells, this advance
may eventually lead to successful pro-
duction of mature human oocytes in vitro
for such research purposes. This may
relieve some of the ethical and financial
barriers presently involved in oocyte
donation for SCNT.ll 12, June 6, 2013 ª2013 Elsevier Inc. 637
Figure 1. Current Modalities for Deriving Pluripotent Cell Lines and Their Potential Utility in Autologous Cell Therapies
Top panel: hESCs are usually derived from IVF-generated human embryos. Their genetic composition is unique to the individual embryo and they are thus not
capable of providing genetically matched cells/organs/tissues for cell implantation therapies for other individuals. Middle panel: SCNT-ESCs rely on the genetic
contribution of two sources: the nuclear donor (orange) and the oocyte (white), the latter of which retains its own mitochondrial genome. Mitochondria are indi-
cated in blue (healthy) and orange (defective). For individuals with genetic mitochondrial diseases, these cell lines could provide autologous cells containing
healthy mitochondria from the oocyte donor along with the genetic contribution of their own nucleus, thus at once ensuring immunocompatibility and healthy
mitochondria of the resulting cell lines. Bottom panel: iPSCs come from direct, factor-mediated reprogramming of somatic cells from children or adults. The re-
sulting cells contain the entire genetic composition of the somatic cell donor, both mitochondrial and nuclear. Therefore pluripotent cell lines derived from indi-
viduals with genetic mitochondrial disease (orange) will continue to harbor those defects.
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PreviewsThe generation of SCNT-ESC lines in
this study shows it is feasible to generate
cellular derivatives that may be more
robust, genetically stable, and ‘‘adult-
like’’ due to the absence of somatic cell
memory and without the introduction of
genetic elements and oncogenes used
to derive iPSCs. Time will be needed to
test whether this is the case, and whether
SCNT-ESC-derived cells, tissues, and
organs fair better in differentiation to
mature, functional cells and in graft
survival. What is certain is that this
breakthrough will rekindle interest in the
potential of human SCNT for basic
research and cell therapies.638 Cell Stem Cell 12, June 6, 2013 ª2013 EREFERENCES
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